{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:09Z","timestamp":1761238389696},"reference-count":12,"publisher":"Portland Press Ltd.","issue":"9","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:p>Despite recent advances in basic and clinical science, dementia remains an area of high unmet medical need. The role of cerebrovascular mechanisms in the pathogenesis and progression of cognitive and functional impairment in dementia is being revived. In order to facilitate the development of therapeutic approaches, it is critical that a number of fundamental elements are integrated into research strategies investigating cerebrovascular pathologies as these will maximize the opportunity of bringing medicines to patients in a timely manner.<\/jats:p>","DOI":"10.1042\/cs20160724","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:20:22Z","timestamp":1492647622000},"page":"799-802","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms of vascular disease in dementia: what does industry want to know?"],"prefix":"10.1042","volume":"131","author":[{"given":"Paul\u00a0B.","family":"Wren","sequence":"first","affiliation":[{"name":"Neurosciences, GlaxoSmithKline, Stockley Park, Uxbridge UB11 1BS, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Hill","sequence":"additional","affiliation":[{"name":"Ixico PLC, Griffin Court, 15 Long Lane, London EC1A 9PN, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Neurosciences, GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge CB2 0GG, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"2021113010553127700_B1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.neuron.2013.10.008","article-title":"The pathobiology of vascular dementia","volume":"80","author":"Iadecola","year":"2013","journal-title":"Neuron"},{"key":"2021113010553127700_B2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","article-title":"Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease","volume":"131","author":"Kalaria","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"2021113010553127700_B3","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O'Brien","year":"2015","journal-title":"Lancet"},{"key":"2021113010553127700_B4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Inter. Med."},{"key":"2021113010553127700_B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"2021113010553127700_B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","article-title":"A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimer's Dement. Transl. Res. Clin. Interven."},{"key":"2021113010553127700_B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"2021113010553127700_B8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11910-013-0415-7","article-title":"Contemplating Alzheimer's disease and the contribution of white matter hyperintensities","volume":"13","author":"Brickman","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"2021113010553127700_B9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1365-2125.2012.04423.x","article-title":"Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials","volume":"75","author":"Rollin-Sillaire","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021113010553127700_B10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.drudis.2016.01.003","article-title":"Translational medicine guide transforms drug development processes: the recent merck experience","volume":"21","author":"Dolgos","year":"2016","journal-title":"Drug Discov. Today"},{"key":"2021113010553127700_B11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1161\/STROKEAHA.116.012066","article-title":"Vascular contributions to cognitive impairment and dementia: topical review of animal models","volume":"47","author":"Madigan","year":"2016","journal-title":"Stroke"},{"key":"2021113010553127700_B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-016-0806-z","article-title":"First translational \u2018Think Tank\u2019 on cerebrovascular disease, cognitive impairment and dementia","volume":"14","author":"Barone","year":"2016","journal-title":"J. Transl. Med."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/9\/799\/445439\/cs1310799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/9\/799\/445439\/cs1310799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:47:13Z","timestamp":1638272833000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/131\/9\/799\/71756\/Mechanisms-of-vascular-disease-in-dementia-what"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20160724","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}